Abstract
There is an emerging concern that the COVID-19 pandemic could harm psychological health and exacerbate suicide risk. Utilising month-level suicide records covering the entire Japanese population in 1,848 administrative units, we assessed whether suicide mortality changed during the pandemic. Employing difference-in-difference estimation, we found that monthly suicide rates declined by 14% during the initial five months (February to June 2020), which could be due to a number of complex reasons, including the government’s generous subsidies, reduced working hours, and school closure. In contrast, monthly suicide rates increased by 16% in the second wave (July to October 2020), with the magnitude greater among females (37%) and children and adolescents (49%). The adverse impact of the COVID-19 pandemic may remain, while its modifiers (e.g. government subsidies) may not be sustained for long. Hence, effective suicide prevention, particularly among vulnerable populations, should be an important public health consideration.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Shohei Okamoto is supported by the postdoctoral fellowship of the Japan Society for the Promotion of Science (No. 20J00394) and the Murata Science Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was not requred as this research is based on secondary analysis of publicly available data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
4
Blogs/Media
Author Videos